首页 | 本学科首页   官方微博 | 高级检索  
     


Liver transplantation and waitlist mortality for HCC and non‐HCC candidates following the 2015 HCC exception policy change
Authors:Tanveen Ishaque  Allan B. Massie  Mary G. Bowring  Christine E. Haugen  Jessica M. Ruck  Samantha E. Halpern  Madeleine M. Waldram  Macey L. Henderson  Jacqueline M. Garonzik Wang  Andrew M. Cameron  Benjamin Philosophe  Shane Ottmann  Anne F. Rositch  Dorry L. Segev
Abstract:Historically, exception points for hepatocellular carcinoma (HCC) led to higher transplant rates and lower waitlist mortality for HCC candidates compared to non‐HCC candidates. As of October 2015, HCC candidates must wait 6 months after initial application to obtain exception points; the impact of this policy remains unstudied. Using 2013‐2017 SRTR data, we identified 39  350 adult, first‐time, active waitlist candidates and compared deceased donor liver transplant (DDLT) rates and waitlist mortality/dropout for HCC versus non‐HCC candidates before (October 8, 2013‐October 7, 2015, prepolicy) and after (October 8, 2015‐October 7, 2017, postpolicy) the policy change using Cox and competing risks regression, respectively. Compared to non‐HCC candidates with the same calculated MELD, HCC candidates had a 3.6‐fold higher rate of DDLT prepolicy (aHR = 3.49 3.69 3.89) and a 2.2‐fold higher rate of DDLT postpolicy (aHR = 2.09 2.21 2.34). Compared to non‐HCC candidates with the same allocation priority, HCC candidates had a 37% lower risk of waitlist mortality/dropout prepolicy (asHR = 0.54 0.63 0.73) and a comparable risk of mortality/dropout postpolicy (asHR = 0.81 0.95 1.11). Following the policy change, the DDLT advantage for HCC candidates remained, albeit dramatically attenuated, without any substantial increase in waitlist mortality/dropout. In the context of sickest‐first liver allocation, the revised policy seems to have established allocation equity for HCC and non‐HCC candidates.
Keywords:cancer/malignancy/neoplasia  clinical research/practice  disparities  graft survival  liver disease: malignant  liver transplantation/hepatology  organ allocation
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号